{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to insufficient number of participants with events (progressive disease or death)","groupId":"OG000","lowerLimit":"2.66","upperLimit":"NA","value":"NA"},{"comment":"Not estimable due to insufficient number of participants with events (progressive disease or death)","groupId":"OG001","lowerLimit":"2.50","upperLimit":"NA","value":"8.2"},{"groupId":"OG002","lowerLimit":"2.76","upperLimit":"11.30","value":"11.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"DOR defined as the time from the first determination of an objective response until progression or death, whichever occurs first, as assessed by the investigator using Lugano criteria with LYRIC modification for cohorts 1 and 2 and ISCL/EORTC guidelines for cohort 3.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed or refractory (R/R) extranodal natural killer-/T-cell lymphoma (ENKTL; nasal or non-nasal type) were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG000","title":"Cohort 1: ENKTL"},{"description":"Participants with other R/R mature T-cell neoplasms \\[limited to peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large-cell lymphoma (ALCL)\\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG001","title":"Cohort 2: PTCL-NOS, AITL, and ALCL"},{"description":"Participants with R/R cutaneous T-cell lymphoma \\[limited to mycosis fungoides (MF) and Sèzary syndrome (SS)\\] were treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle until disease progression, intolerable toxicity, or treatment discontinuation for any other reason (21 days per cycle)","id":"OG002","title":"Cohort 3: MF and SS"}],"paramType":"MEDIAN","populationDescription":"Safety analysis set includes all participants who received at least one dose of study drug; Duration of response was summarized for responders (participants who achieved a partial or complete response).","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years and 1 week","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}